Bristol-Myers Squibb Co. under the ticker symbol BMY. Here is some more information that we have about Bristol-Myers Squibb Co.

Get our alerts and future stock picks in your email inbox

What you feel with this company ? Are you willing to
Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising ENFAMIL products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company is also developing various compounds, which are in phase III clinical trials, including Apixaban, Saxagliptin, Dapagliflozin, Ipilimumab, Belatacept, XL-184, Tanespimycin, and Brivanib. In addition, it develops a therapeutic class of biologics called ADNECTINS. BMS has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; Gilead Sciences, Inc.; Medarex, Inc.; and AstraZeneca PLC, as well as collaborations with Pfizer Inc.; Exelixis, Inc.; and KineMed Inc. It also has an agreement with PDL BioPharma, Inc. for the development and commercialization of anti-CS1 antibody and elotuzumab for multiple myeloma; and a strategic alliance with Ensemble Discovery Corporation. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
28,000 Employees
Last Reported Date: 02/14/14
Founded in 1887
Last $52.50 USD
Change Today +0.66 / 1.27%
Volume 7.5M
As of 8:04 PM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - $57.49
52 Week Low
06/5/14 - $46.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Request Investor Kit
BMY:US Advanced Stock Chart

bristol-myers squibb co (BMY) Related Bloomberg News

Bristol-Myers Tops Estimates on Strong Drug Sales
AstraZeneca, Bristol-Myers Won’t Face Kickback Lawsuit
Novartis Leukemia Treatment Yields High Remission Rate
Bristol-Myers Gives Up on Hepatitis C Combination in U.S.
You Talking About Your Weight on Facebook? Hedge Funds Are Listening

bristol-myers squibb co (BMY) Related News

What's the Dollar Value of Online Patient Chatter?
It's Not Just Disruption: More Management Wisdom You Should Doubt
'Miracle' Data Could Lead to Cancer Cures
Buying Prescription Drugs Online Without Getting Burned

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO(R) (nivolumab) and IMBRUVICA(R) (ibrutinib) in Non-Hodgkin Lymphoma

Bristol-Myers Squibb Company, Pharmacyclics Inc. and Janssen Research & Development, LLC announced they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor OPDIVO(R) (nivolumab) in combination with IMBRUVICA(R) (ibrutinib), an oral Bruton's tyrosine kinase (BTK) inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Bristol-Myers Squibb has proposed the name OPDIVO (pronounced op-dee-voh), which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body's own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies.

Bristol-Myers Squibb Company Presents at BioFlorida Annual Conference, Oct-13-2014 08:50 AM

Bristol-Myers Squibb Company Presents at BioFlorida Annual Conference, Oct-13-2014 08:50 AM. Venue: Harbor Beach Marriott, Ft. Lauderdale, Florida, United States. Speakers: Lee Evans, Executive Director and Site Leader, North America Center.

Bristol-Myers Squibb Company and MD Anderson Cancer Center of the University of Texas Announce Immuno-Oncology Partnership

Bristol-Myers Squibb and the MD Anderson Cancer Centre of the University of Texas have announced their immuno-oncology collaboration that will focus on advancement of novel therapies for the treatment of acute or chronic leukaemia and other haematologic malignancies. The clinical research partnership will include programmed cell death protein 1 (PD-1) inhibitor Opdivo (nivolumab) and CTLA-4 inhibitor Yervoy (ipilimumab), as well as three undisclosed early-stage immuno-oncology candidates in BMS's pipeline. Up to 10 Phase I and Phase II clinical trials will be launched and conducted by the centre, investigating several monotherapy and combination regimens to treat acute myeloid leukaemia, chronic lymphocytic leukaemia, chronic myeloid leukaemia, myelodysplastic syndrome, and myelofibrosis. The two partners will determine if additional clinical trials will be launched at a later time.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $52.50 USD +0.66

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $59.52 USD +2.62
Amgen Inc $147.25 USD +3.61
AstraZeneca PLC 4,298 GBp -37.00
Biogen Idec Inc $316.06 USD +6.99
Novo Nordisk A/S kr267.80 DKK -1.70

Industry Analysis


Industry Average

Valuation BMY Industry Range
Price/Earnings 32.1x
Price/Sales 5.3x
Price/Book 5.6x
Price/Cash Flow 32.0x
TEV/Sales 4.4x

Sponsored Financial Commentaries

Sponsored Links

Will Bristol-Myers
AstraZeneca, Bristol-Myers Won’t Face Kickback Lawsuit
How Will Bristol-Myers Squibb
Bristol-Myers Collaborates for Opdivo-Imbruvica Combo
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss CMSTO Highlights
[Business Wire] - Bristol-Myers Squibb Company will host a teleconference on Friday, October 31, 2014, at 2:30 p.m. EDT to review data presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology in Chicago.
BUZZ-Innate Pharma: Citi lauds French biotech firm's cancer work
Bristol-Myers Gives Up on US Approval of 2-Drug HCV Combo
Bristol-Myers Squibb Statement on Sustiva
[Business Wire] - Bristol-Myers Squibb Company has successfully resolved all outstanding U.S. patent litigation relating to efavirenz, an active ingredient contained in our Sustiva and Atripla products.
Cramer: Trust the Bristol-Myers Theorem
[$$] Bristol-Myers Drops Hepatitis C Dual Regimen in U.S.
[at The Wall Street Journal] - Bristol-Myers Squibb said it won’t pursue FDA approval of a dual regimen of drugs to treat hepatitis C, citing the “rapidly evolving” treatment landscape in the U.S.
Why Bristol-Myers Squibb
Bristol-Myers Pulls FDA Filing For 2-Drug Hep C Combo
UPDATE 1-Bristol-Myers pulls U.S. marketing application for hepatitis C treatment
[Reuters] - Bristol-Myers Squibb said it withdrew its U.S. Bristol-Myers is racing against Merck & Co and AbbVie to try and cut the treatment time by half and avoid side effects from older standard drugs interferon and ribavirin. Bristol-Myers' two-drug combination treatment, in a late-stage study in April, showed that it could cure HCV infections in 24 weeks in 82 percent of patients who were unable to tolerate interferon and ribavirin.
Bristol-Myers Gives Up on Hepatitis C Combination in U.S.